Diagnostic Performance of Serum Asialo α<sub>1</sub>-Acid Glycoprotein Levels to Predict Liver Cirrhosis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: To date, studies on various noninvasive techniques have been suggested to evaluate the degree of liver fibrosis. We aimed to investigate the diagnostic performance of serum asialo α1-acid glycoprotein (AsAGP) in the diagnosis of liver cirrhosis compared with chronic hepatitis for clinically useful result. Methods: We conducted a case-control study of 96 patients with chronic liver disease. Chronic hepatitis was defined as the presence of chronic liver disease on ultrasonography, with a liver stiffness of less than 5.0 kPa as shown on magnetic resonance elastography (MRE). Liver cirrhosis was defined as liver stiffness of more than 5.0 kPa on MRE. The serum AsAGP concentration was compared between the two groups. Results: Serum AsAGP levels were significantly higher in patients with cirrhosis than in those with chronic hepatitis (1.83 μg/mL vs 1.42 μg/mL, p<0.001). Additionally, when comparing patients in each cirrhotic group (Child-Pugh grades A, B, and C) to those with chronic hepatitis, AsAGP levels were significantly higher in all the cirrhotic groups (p<0.05, p<0.01, p<0.001, respectively). The sensitivity and specificity of AsAGP for detecting cirrhosis were 79.2% and 64.6%, respectively, and the area under the curve value was 0.733. The best diagnostic cutoff to predict cirrhosis was 1.4 μg/mL. AsAGP and bilirubin were found to be independent risk factors for the prediction of cirrhosis in the logistic regression analysis. Conclusions: Serum AsAGP showed an acceptable diagnostic performance in predicting liver cirrhosis.
Abstract
Background/Aims: To date, studies on various noninvasive techniques have been suggested to evaluate the degree of liver fibrosis. We aimed to investigate the diagnostic performance of serum asialo α1-acid glycoprotein (AsAGP) in the diagnosis of liver cirrhosis compared with chronic hepatitis for clinically useful result. Methods: We conducted a case-control study of 96 patients with chronic liver disease. Chronic hepatitis was defined as the presence of chronic liver disease on ultrasonography, with a liver stiffness of less than 5.0 kPa as shown on magnetic resonance elastography (MRE). Liver cirrhosis was defined as liver stiffness of more than 5.0 kPa on MRE. The serum AsAGP concentration was compared between the two groups. Results: Serum AsAGP levels were significantly higher in patients with cirrhosis than in those with chronic hepatitis (1.83 μg/mL vs 1.42 μg/mL, p<0.001). Additionally, when comparing patients in each cirrhotic group (Child-Pugh grades A, B, and C) to those with chronic hepatitis, AsAGP levels were significantly higher in all the cirrhotic groups (p<0.05, p<0.01, p<0.001, respectively). The sensitivity and specificity of AsAGP for detecting cirrhosis were 79.2% and 64.6%, respectively, and the area under the curve value was 0.733. The best diagnostic cutoff to predict cirrhosis was 1.4 μg/mL. AsAGP and bilirubin were found to be independent risk factors for the prediction of cirrhosis in the logistic regression analysis. Conclusions: Serum AsAGP showed an acceptable diagnostic performance in predicting liver cirrhosis.
참고문헌 (14)
- Poynard T, "A comparison of fibrosis progression in chronic liver diseases", J Hepatol, 38, pp.257~265 (2003)
- Friedman SL, "Mechanisms of hepatic fibrogenesis", Gastroenterology, 134, pp.1655~1669 (2008)
- Lambrecht J, "Prospects in non-invasive assessment of liver fibrosis: liquid biopsy as the future gold standard?", Biochim Biophys Acta Mol Basis Dis, 1864(4 Pt A), pp.1024~1036 (2018)
- Wong MW, "Evidence for reduced uptake of asialo-alpha 1-acid glycoprotein during the acute phase response to inflammation", Life Sci, 25, pp.827~833 (1979)
- Hochepied T, "Alpha(1)-acid glycoprotein : an acute phase protein with inflammatory and immunomodulating properties", Cytokine Growth Factor Rev, 14, pp.25~34 (2003)
- Kindberg GM, "The effect of vanadate on receptor-mediated endocytosis of asialoorosomucoid in rat liver parenchymal cells", J Biol Chem, 265, pp.8999~9005 (1990)
- Malaba L, "Retinol-binding protein and asialo-orosomucoid are taken up by different pathways in liver cells", J Biol Chem, 270, pp.15686~15692 (1995)
- Kim KA, "Diagnostic accuracy of serum asialo-alpha1-acid glycoprotein concentration for the differential diagnosis of liver cirrhosis and hepatocellular carcinoma", Clin Chim Acta, 369, pp.46~51 (2006)
- Chang W, "Liver fibrosis staging with MR elastography : comparison of diagnostic performance between patients with chronic hepatitis B and those with other etiologic causes", Radiology, 280, pp.88~97 (2016)
- Cardoso AC, "Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C", Liver Int, 32, pp.612~621 (2012)
- Venkatesh SK, "Magnetic resonance elastography of liver : technique, analysis, and clinical applications", J Magn Reson Imaging, 37, pp.544~555 (2013)
- Singh S, "Diagnostic performance of magnetic resonance elastography in staging liver fibrosis : a systematic review and meta-analysis of individual participant data", Clin Gastroenterol Hepatol, 13, pp.440~451 (2015)
- Kang BK, "Feasibility of modified Dixon MRI techniques for hepatic fat quantification in hepatic disorders : validation with MRS and histology", Br J Radiol, 91, pp.20170378~ (2018)
- Noureddin M, "Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials", Hepatology, 58, pp.1930~1940 (2013)